Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Blood|May 9, 2001
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBOP N Mainwaring, D Cunningham, W Gregory, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2010
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPCRoberto Pili, Mark A Rosenthal, Paul N Mainwaring, et al.
British Journal of Cancer|December 17, 2008
Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancerM J McKeage, J Von Pawel, M Reck, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2017
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANAStéphane Oudard, Karim Fizazi, Lisa Sengeløv, et al.
The Lancet. Oncology|September 15, 2018
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trialFred Saad, David Cella, Ethan Basch, et al.
ACS Nano|July 21, 2018
Design and Clinical Verification of Surface-Enhanced Raman Spectroscopy Diagnostic Technology for Individual Cancer Risk PredictionKevin M Koo, Jing Wang, Renée S Richards, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 27, 2026
Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation FrameworkKevin M Koo, Grant Phillips, Sriganesh Srihari, et al.
The Lancet. Oncology|October 1, 2013
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trialEthan Basch, Karen Autio, Charles J Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2019
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancerE J Small, F Saad, S Chowdhury, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerE G Chiorean, D D Von Hoff, M Reni, et al.
Pageof 4